LACY LOEB: Open Payments
NPI 1366813545 · TROY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 27 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $760 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $107 |
| Novo Nordisk Inc | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Dexcom, Inc. | 2 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Exact Sciences Corporation | 1 | $23 |
| PFIZER INC. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
Products named: UBRELVY, REXULTI, AIRSUPRA, CAPLYTA, Wegovy, Dexcom G6 Transmitter, JARDIANCE, QULIPTA.
Industry payments across MO — which companies pay providers there.
